• Markets
  • icon
  • Companies
IMM · ASX

Immutep Ltd (ASX:IMM)

AU$0.46

 0.02 (4.598%)
ASX:Live
17/05/2024 04:10:34 PM
Recent Price upgrade HALO Price Momentum HALO Ords HALO Consensus Value GROWTH AUS +2
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

IMM Overview

IMM Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Weak

About IMM

Telephone

Address

Description

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987, and is headquartered in Sydney, Australia.

IMM Price Chart

Key Stats

Market Cap

AU$517.14M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.26 - 0.49

Trade Value (12mth)

AU$133,120.00

1 week

0%

1 month

28.17%

YTD

31.88%

1 year

32.05%

All time high

4.106790065765381

Key Fundamentals

EPS 3 yr Growth

33.000%

EBITDA Margin

N/A

Operating Cashflow

-$35m

Free Cash Flow Return

-30.30%

ROIC

-34.20%

Interest Coverage

-2,101.60

Quick Ratio

13.80

Other Data

Shares on Issue (Fully Dilluted)

1186m

HALO Sector

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.04

IMM Announcements

Latest Announcements

Date Announcements

15 May 24

AIPAC-003 safety lead-in data presented at ESMO Breast 2024

×

AIPAC-003 safety lead-in data presented at ESMO Breast 2024

02 May 24

Positive initial data in phase 2 Soft Tissue Sarcoma trial

×

Positive initial data in phase 2 Soft Tissue Sarcoma trial

29 April 24

Immutep Quarterly Activities Report and Appendix 4C

×

Immutep Quarterly Activities Report and Appendix 4C

24 April 24

Positive preliminary topline results from TACTI-003 Cohort B

×

Positive preliminary topline results from TACTI-003 Cohort B

18 April 24

CHDR to conduct first-in-human phase 1 trial of IMP761

×

CHDR to conduct first-in-human phase 1 trial of IMP761

17 April 24

Positive Feedback received from Spanish Medicines Agency

×

Positive Feedback received from Spanish Medicines Agency

11 April 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

08 March 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

05 March 24

First Clinical Data announced from 90mg Dosing of Efti

×

First Clinical Data announced from 90mg Dosing of Efti

28 February 24

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

26 February 24

Becoming a substantial holder

×

Becoming a substantial holder

22 February 24

Change in substantial holding

×

Change in substantial holding

21 February 24

Immutep Investor Update

×

Immutep Investor Update

20 February 24

Change in substantial holding

×

Change in substantial holding

15 February 24

Becoming a substantial holder

×

Becoming a substantial holder

14 February 24

Appointment of Non-Executive Director

×

Appointment of Non-Executive Director

14 February 24

Appendix 3X - Anne Anderson

×

Appendix 3X - Anne Anderson

14 February 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

31 January 24

Notification regarding unquoted securities - IMM

×

Notification regarding unquoted securities - IMM

30 January 24

Immutep Quarterly Activities Report and Appendix 4C

×

Immutep Quarterly Activities Report and Appendix 4C

15 January 24

Change in substantial holding

×

Change in substantial holding

08 January 24

Immutep Corporate Presentation

×

Immutep Corporate Presentation

04 January 24

First Patient Dosed in Urothelial Cancer INSIGHT-005 Trial

×

First Patient Dosed in Urothelial Cancer INSIGHT-005 Trial

22 December 23

Change of Registered Office Address

×

Change of Registered Office Address

21 December 23

PEI provides constructive feedback for ph3 lung cancer trial

×

PEI provides constructive feedback for ph3 lung cancer trial

IMM Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.05 -0.04 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.05 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -49.7 24.7 -17.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.03 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock 6.7 -58.2 8.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.4 -12.3 -12.6 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.10 0.11 0.11 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.08 0.10 0.11 Lock Lock Lock
     Growth % Lock Lock Lock Lock 268.8 19.4 10.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 595 849 892 Lock Lock Lock
Basic m Lock Lock Lock Lock 595 849 892 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -100.0 N/A -100.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 21 36 43 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A 8.6 -8.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -1,111.2 N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A 1,211 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -21 -36 -43 Lock Lock Lock
     Growth % Lock Lock Lock Lock -11.4 -69.3 -18.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -21,317.2 N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -24 -38 -45 Lock Lock Lock
     Growth % Lock Lock Lock Lock -10.3 -63.2 -17.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -22,528.4 N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -30 -32 -40 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -30 -32 -40 Lock Lock Lock
     Growth % Lock Lock Lock Lock -122.0 -7.7 -23.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -18,906.5 N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -18 -30 -35 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 53 50 76 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -18 -30 -35 Lock Lock Lock
     Growth % Lock Lock Lock Lock -62.6 -71.3 -17.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -177.6 N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 61 80 123 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 82 102 147 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 3 2 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -58 -78 -122 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 9 8 11 Lock Lock Lock
Equity $m Lock Lock Lock Lock 73 94 136 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 76 96 138 Lock Lock Lock
     Growth % Lock Lock Lock Lock 79.7 26.0 43.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -36.5 -31.5 -27.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -40.8 -34.2 -29.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -39.7 -44.7 -38.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -50.6 -37.6 -34.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -29.9 -35.2 -30.3 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -2,183.1 -392.9 -2,101.6 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.7 2.2 2.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -78.9 -83.2 -89.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 12.8 14.2 13.8 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 12.8 14.2 13.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 88.6 88.1 91.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -330.3 -471.3 -361.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A 1,682.3 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A -18,906.5 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A -31.5 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -36.5 -31.5 -27.1 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -40.8 -34.2 -29.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -40.8 -34.2 -29.2 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A 15,530.4 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A 15,530.4 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 305.4 414.9 735.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -305.4 15,115.5 -735.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.04%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

IMM Shortsell

Frequently Asked Questions

The current share price of Immutep Ltd (IMM:ASX) is AU$0.46.
The 52-week high share price for Immutep Ltd (IMM:ASX) is AU$0.49.
The 52-week low share price for Immutep Ltd (IMM:ASX)? is AU$0.26.
Immutep Ltd (IMM:ASX) does not pay a dividend.
Immutep Ltd (IMM:ASX) does not pay a dividend.
Immutep Ltd (IMM:ASX) has a franking level of 0.0%.
Immutep Ltd (IMM:ASX) is classified in the Healthcare.
The current P/E ratio for Immutep Ltd (IMM:ASX) is .